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ABSTRACT
Aim To investigate the prevalence of derepressed/partly derepre-
ssed/inducible and ESBL/AmpC-producing Enterobacter cloacae 
isolates and treatment options for infections associated with those 
isolates.
Methods Antibiotic susceptibility was determined by disc diffusi-
on and broth microdilution according to CLSI guidelines. Double-
disk synergy test (DDST) was performed in order to screen for 
ESBLs and combined disk test with phenylboronic acid to detect 
AmpC β -lactamases. PCR was used to detect blaESBL/blacarb genes. 
Genetic relatedness of the strains was determined by pulsed-field-
gel-electrophoresis (PFGE).
Results Among 14 isolates with the ESBL positive E. cloaceae 
producing isolates, four (28.6%), nine (64.3%) and one (7.1%) 
isolates were derepressed/partly derepressed and inducible AmpC 
producers. Eleven (out of 14) isolates were resistant to cefotaxime, 
ceftazidime, ceftriaxone, aminoglycosides and fluoroquinolones. 
All isolates were susceptible to imipenem and meropenem, 79% 
to cefepime. Five (out of 14; 35.7%) isolates (four derepressed and 
one inducible AmpC carrying E. cloaceae) were negative in phe-
notypic test for ESBLs, but positive for broad spectrum TEM-1 
β-lactamase. One (out of four derepressed) also produced CMY-2 
β-lactamase. Four (out of nine) partly derepressed isolates were 
positive with the DDST, but did not yield PCR products with 
primers targeting TEM, SHV and CTX-M beta-lactamases. Four 
positive partly derepressed isolates carried a blaCTX-M-1 gene, two 
bla
OXA-1
 one bla
CTX-M-15, OXA-1 
 and one bla
CTX-M-28, OXA-1 
(n=1). 
Conclusion Microbiology laboratories must be able to detect and 
recognize AmpC-carrying isolates in a timely manner, especially 
those that are falsely susceptible in vitro to drugs that may be con-
sidered for therapy of infected patients.
Key words: chromosomal AmpC, ESBL, antibiotic resistance
Medicinski Glasnik, Volume 15, Number 1, February 2018
2
INTRODUCTION
Enterobacter cloacae is a nosocomial pathogen 
that can cause a range of infections such as bac-
teremia, lower respiratory tract infection, skin 
and soft tissue infections, urinary tract infections, 
endocarditis, intra-abdominal infections, septic 
arthritis, osteomyelitis, and ophthalmic infecti-
ons (1). It has intrinsic chromosomal resistance 
to penicillins, first generation of cephalosporins, 
cephamycins and beta (β)-lactam/- β lactama-
se inhibitors due to the chromosomal  AmpC 
β-lactamase (2). Overexpression of AmpC beta-
lactamase causes resistance to third generation 
of cephalosporins.  There are two main reasons 
for absence of guidelines for extended-spectrum 
beta-lactamase (ESBL) detection in Enterobac-
teriaceae with inducible chromosomal AmpC 
β-lactamases production, including Enterobacter 
spp. (3). First, AmpC expression may mask the 
synergy required for detection of ESBLs based 
on the synergy between third-generation cepha-
losporins and clavulanic acid (4), and second, the 
significance of ESBL detection in Enterobacte-
riaceae with inducible AmpC expression  is con-
sidered to have limited therapeutic consequence 
(5,6). Cephalosporin resistance in E. cloacae is 
mainly due by overproduction (derepression) 
of the class-I  beta-lactamase encoded by the 
chromosomal AmpC gene. Stable derepressed 
mutants are segregated from inducible strains at 
relatively high frequencies (7). 
Classification of E. cloacae strains having dere-
pressed, partly derepressed, or inducible AmpC 
production was determined by Sanders and Pai 
methods (8,9), in which cefoxitin-cefotaxime an-
tagonist test should be performed (8,9). Prevalence 
of these mutants was largerly investigated (10,11), 
because  therapeutic failures with cephalosporin 
treatment have been associated with the selection 
and ultimate dominance of these variants (7,12). 
Cefepime was a drug of choice for the treatment of 
even infections caused by E. cloacae strains with 
AmpC overproduction (8), but reduced susceptibi-
lity to cefepime appeared very soon (13).
There has been no description of chromosomal 
AmpC- β-lactamases in Enterobacter spp. in Bo-
snia and Herzegovina (B&H) so far. During the 
2009-2010 investigation of infections caused by 
ESBL-producing Gram-negative bacteria inter-
mediate susceptibillity to cefepime was noticed 
in 43% (out of 30 ESBL-producing) E. clacae 
isolates by disc-diffusion, as well as MIC of >16 
µg/mL for cefepime was found in 57% isolates 
(Ibrahimagić, unpublished data). It was prompted 
us to investigate mechanisms of reduced cefepi-
me susceptibility, e.g. types of chromosomal 
AmpC beta-lactamases and molecular characte-
ristics of ESBLs in these isolates.
The aim of the study was to investigate the 
occurrance of derepressed, partly derepressed 
and inducible AmpC and extended-spectrum 
β-lactamases in  E. cloacae isolates causing in- 
and outpatient infections in Zenica-Doboj Can-
ton, Bosnia and Herzegovina, and their antibiotic 
susceptibillity according to the breakpoint chan-
ges in  CLSI-2009/CLSI-2014 documents. 
MATERIALS AND METHODS
Setting, bacterial isolates and study design
During the period December 2009 to May 2010, 
a total of 9092 and 16037 samples from inpati-
ents and outpatients, respectively, were collected 
in the Microbiology Laboratory of the Cantonal 
Hospital Zenica.  
Among inpatients, Gram-negative bacteria were 
isolated from 1254 (13.8%) samples, of which 
ESBL and/or AmpC β-lactamase producing bac-
teria were detected in 126 (out of 1254, 10.0%) 
samples; Enterobacter spp. were isolated from 
32 (out of 1254, 2.6%) samples, of which 14 
(out of 32; 43.7%) were ESBL and/or AmpC 
β-lactamase producing isolates. Among outpati-
ents, Gram-negative bacteria were isolated from 
2857 (17.8%) samples, of which 184 (6.4%) were 
ESBL- and/or AmpC β-lactamase producing bac-
teria; Enterobacter spp. were isolated from 22 
(out of 2857; 0.8%) samples, of which 16 (out of 
22; 72.7%) were β-lactamase producing isolates. 
Among 30 ESBL- and /or AmpC β-lactamase-
producing Enterobacter spp. (14 in- and 16 out-
patients), 14 (eight inpatient and six outpatient) 
were available for further analysis. 
An institutional review board approval from the 
Ethics Committee of the Cantonal Hospital Zenica 
was obtained prior to the initiation of the study.
Antimicrobial susceptibility testing
Susceptibility testing to 14 antimicrobials (Oxo-
id, Basingstoke, UK) initially was performed by 
3disk diffusion method according to CLSI (Cli-
nical and Laboratory Standards Institute) stan-
dard procedure:  amoxycillin (AMX; 30 µg), 
amoxycillin+clavulanic acid (AMC; 20+10 µg), 
cefalexin (CN; 30 µg), cefazolin (CZ; 30 µg), 
cefuroxime (CXM; 30 µg), ceftazidime (CAZ; 
30 µg),  cefotaxime (CTX; 30 µg), ceftriaxone 
(CRO; 30 µg), cefoxitin (FOX; 30 µg), cefepime 
(FEP; 30 µg), imipenem (IMP; 10 µg), merope-
nem (MEM; 10 µg), gentamicin (GM; 10 µg), 
and ciprofloxacin (CIP; 5 µg) (14). E. coli ATCC 
25922 were used as quality control strain.
Susceptibility testing to 12 antimicrobials was 
performed by a two-fold microdilution technique 
according to CLSI (Clinical and Laboratory Stan-
dards Institute) standard procedure (15), AMC, 
CZ, CXM, CAZ, CTX, CRO, FOX, FEP, IMP, 
MEM, GM, CIP. Multi-drug resistance (MDR) 
was defined as resistance to three or more anti-
microbial classes (2nd, 3rd or 4th generation cepha-
losporins, aminoglycosides, fluroquinolones and 
carbapenems (8).
E. coli ATCC 25922 (ESBL negative) and K. 
pneumoniae 700603 (ESBL positive) were used 
as quality control strains.
Detection of ESBLs, AmpC beta-lactamases and 
carbapenemases
ESBL production was determined by double-
disk-synergy test (DDST). Overnight broth 
culture of test strain was diluted in saline, adju-
sted to McFarland standard suspension 0.5 and 
inoculated onto Mueller-Hinton agar (MH); disk 
containing  amoxycillin/clavulanate (20/10 µg) 
was placed in the middle of the plate and surro-
unded (20 mm distance centre to centre) by disks 
containing  cefotaxime (5 µg), ceftriaxone (30 
µg), ceftazidime (10 µg), and cefepime (30 µg) 
(Becton-Dickinson, USA). Plates were incubated 
overnight at 37 °C. Any distortion or increase of 
the inhibition zone of ≥5 mm around cefalospo-
rine disks toward amoxycillin/clavulanate disk 
was indicative of ESBL production (14). 
Production of ESBLs was confirmed by CLSI 
combined disk test. Disks containing 30 μg of ce-
fotaxime and ceftazidime, and disks containing a 
combination of the two drugs plus 10 μL (10μg ) 
of clavulanic acid (Becton Dickinson, USA) were 
placed independently, 20 mm apart, on a lawn 
culture of 0.5 McFarland opacity of the test iso-
late on a Mueller-Hinton agar plate and incubated 
for 18-24 hours at 35°C. Isolates were considered 
ESBL positive if the inhibition zone measured 
around one of the combination disks after over-
night incubation was at least 5 mm larger than that 
of the corresponding cephalosporin disk (14). 
Enterobacter spp. isolates resistant to exten-
ded-spectrum cephalosporins and β-lactam/ 
β-lactamase inhibitor combination (amoxicillin/
clavulanic acid) were screened for production of 
AmpC β -lactamases by combined disk test using 
3-amino phenylboronic acid (PBA) (Sigma-Al-
drich, Steinheim, Germany). The stock solution 
was prepared as previously recommended (16) by 
dissolving PBA (benzeneboronic acid; Sigma-Al-
drich, Steinheim, Germany) in dimethyl sulfoxide 
at a concentration of 20 mg/mL. 20 μL (contai-
ning 400 μg of boronic acid) of the solution was 
dispensed onto antibiotic disks. The disks were 
then dried and used within 60 min. The tests were 
performed by inoculating Mueller-Hinton agar by 
the standard diffusion method and placing disks 
containing five four different β-lactams (CAZ, 10 
µg; CRO, 30 µg; CTX, 5 µg;  FEP, 30 µg) with 
or without boronic acid onto the agar. The agar 
plates were incubated at 37°C overnight. The 
diameter of the growth-inhibitory zone around a 
β-lactam disk with boronic acid was compared 
with that around the corresponding β-lactam disk 
without boronic acid. The test was considered 
positive for the detection of AmpC production 
when the diameter of the growth-inhibition zone 
around a β-lactam disk with boronic acid was ≥5 
mm larger than that around a disk containing the 
β-lactam substrate alone (16). 
Production of carbapenemases of group A or gro-
up B was confirmed by combined disk-test using 
meropenem disks with  PBA and EDTA (ethyle-
nediaminetetraacetic acid) (Sigma-Aldrich, 
Steinheim, Germany), respectively (17). Three 
meropenem (MEM) disks were placed on Mu-
eller-Hinton agar plate inoculated with test strain. 
10 µL of EDTA (300 mg) and PBA (300 mg) was 
added on the first and third disks, respectively. 
The difference in zone size of  ≥5 mm between 
disks with and without  EDTA was suggesting 
production of carbapenemase group B, and the 
difference in zone size of  ≥5 mm between disks 
with and without PBA was suggesting production 
of carbapenemase group A (17).
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Classification of E. cloacae as having inducible, 
partially derepressed, or derepressed AmpC pro-
duction was determined by Sanders et al. method 
using cefoxitin-cefotaxime antagonist test (8,9). 
The ability of cefoxitin to antagonize the activity 
of cefotaxime was determined in disk approxima-
tion tests. A cefoxitin disk producing no zone of 
inhibition was placed on a seeded plate at a dis-
tance from the cefotaxime equivalent to the radi-
us of the zone produced by the cefotaxime when 
tested alone. After overnight incubation at 37 °C, 
the radii of the zone a) between the cefoxitin and 
cefotaxime, and b) on the far side of the cefotaxi-
me were measured. If the radius of a) was smaller 
than that of b) by 4 mm or more, then antagonism 
was considered to have occurred (18).
According to the characteristics of chromosomal 
AmpC β-lactamase production, resistance types 
were defined as follows: derepressed AmpC pro-
ducers were resistant to cefoxitin (zone diameter 
≤14 mm; MIC ≥32 µg/mL), resistant or inter-
mediately susceptible to cefotaxime (≤22 mm; 
MIC ≥16 µg/mL), have a negative cefoxitin–ce-
fotaxime antagonist test and a negative ESBL 
production; partly derepressed AmpC producers 
were resistant to cefoxitin (≤14 mm; MIC ≥32 
µg/mL), resistant or intermediately susceptible to 
cefotaxime (≤22 mm; MIC ≥16 µg/mL), have a 
negative cefoxitin–cefotaxime antagonist test and 
produced ESBL; inducible AmpC producers were 
susceptible to cefoxitin (≥18 mm; MIC ≤16), re-
sistant to cefotaxime (≤22 mm; MIC of  ≥32 µg/
mL), have a positive cefoxitin–cefotaxime anta-
gonist test and a negative ESBL production (8). 
PCR detection of blaCTX-M, blaSHV, blaTEM, and blaKPC 
genes
PCR was used to detect alleles encoding ESBL 
enzymes. 
The presence of blaTEM, blaSHV, blaCTX-M genes was 
investigated by polymerase chain reaction (PCR) 
using primers and conditions as described pre-
viously (19). Designation of bla genes based on 
identified mutations was done according to Bush 
K and Jacoby GA (20). Primers IS26F (5’-GCG-
GTA-AAT-CGT-GGA-GTG-AT-3) and IS26R 
(5’-ATT-CGG-CAA-GTT-TTT-GCT-GT-3’) were 
used to amplify 400 bp fragment spanning the 
link between IS26 insertion sequence and blaCTX-M 
gene in CTX-M producing isolate (21, 22). 
Genes encoding carbapenemases of class A 
(KPC), class B (MBLs belonging to VIM, IMP 
and NDM family) and OXA-48 was detected by 
PCR as described previously (17).
Pulsed-field gel electrophoresis (PFGE) of bacte-
rial DNA
Isolation of genomic DNA, digestion with the 
XbaI restriction enzyme (Invitrogen) and PFGE 
of the resulting fragments was performed as des-
cribed by Kaufman et al (23). The electrophore-
sis was carried out with a CHEF-DRII appara-
tus (Bio-Rad Laboratories, Hercules, CA). The 
PFGE patterns were compared following the 
criteria of Tenover et al (24) and analysed by the 
GelComparII software (Applied Maths, St Mar-
tens, Belgium). 
RESULTS
All AmpC- and/or ESBL producing Enterobacter 
spp. isolates
Infections caused by Enterobacter spp. were re-
presented in our sample with 2.6% and 0.8% (32 
and 22 isolates) prevalence among Gram-negative 
bacteria in inpatients and outpatients, respectively. 
A total of 30 ESBL and/or AmpC beta-lactamase 
producing Enterobacter spp. (14 in- and 16 outpa-
tients) were isolated: 18 (60.0%) were from urine 
samples (12 from outpatients), eight (26.7%) from 
wound infection (four from outpatients), and one 
in each cannula, upper respiratory tract, umbilicus 
and punctate. Samples were collected from six 
different municipalities of Zenica-Doboj Canton, 
predominantly from Zenica city (56.7%). 
Ten (out of 14; 71.4%) inpatients were older than 
60 years of age. The duration of hospitalization 
of patients was 6-40 days (median=15). Four pa-
tients were from Internal Medicine Department, 
four from Intensive Care Unit (ICU) and four 
from Neurology Department, and two from Pa-
ediatric Department. 
Amoxicillin/clavulanic acid and cefazolin were 
mostly used for the treatment of infections asso-
ciated with Enterobacter spp., in five cases each, 
respectively; seven inpatients received corticoste-
roid therapy. Seven patients had positive history 
of hospitalization in previous twelve months, and 
12 inpatients had contacts with persons having 
positive history of recent hospitalization.  
5Eleven (out of 16; 68.7%) outpatients were older 
than 60 years of age. Other data for outpatients 
were missing.
Overall resistance rates to cephalexin, cefuroxi-
me, ceftazidime, ceftriaxone, cefotaxime, and 
cefepime by disk-diffusion method of 100.0%, 
90.0%, 90.0%, 90.0%, 83.0% and 3.3% (50% 
were intermediate), respectively, were noticed in 
30 AmpC- and/or ESBL producing strains. Resi-
stance rates for amoxicillin, cefixime, trimetho-
prim/sulfamethoxazole, amoxicillin/clavulanic, 
nitrofurantoin, gentamicine, ciprofloxacine, and 
amikacin were 100.0%, 95.2%, 80.0%, 60.0%, 
50.0%, 46.1%, 16.7% and 10.0%, respectively. 
All isolates were susceptible to carbapenems 
(data have not shown). 
Characterisation of AmpC/ESBL in 14 Enterobac-
ter cloacae isolates
Fourteen (eight inpatient and six outpatient) out 
of 30 AmpC- and/or ESBL-producing  E. cloacae 
isolates were available for molecular analysis. 
Three isolates originated from Intensive Care 
Unit (ICU) (two wound infections and one as-
pirate), two from Internal Medicine Department 
(upper respiratory tract and urine), two from Pa-
ediatric (smear of umbilicus and urine), and one 
from Neurology Department (urine).  
Protocol Gen-der 
Isolate 
origin Age 
Hospital  
Depar-
tment at 
present 
stay†
Minimal inhibitory concentration (MIC, mg/L) of antibiotics* according to CLSI 
2009/2014  (2009/2014 breakpoint)
β-lactamase
                               
PFGE 
clone
AMC
(≥32/
≥32)
CZ
(≥32/
≥32)
CXM
(≥32/
≥32)
CAZ
(≥32/
≥16)
CTX
(≥64/
≥4)
CRO
(≥64/
≥4)
FOX
(≥32/ 
≥32)
FEP
(≥32/
≥16)
IMI
(≥16/
≥4)
MEM
(≥16/
≥4)
GM
(≥8/
≥16)
CIP
(≥4/
≥4)
17192/10 M Wound 70 ICU >32
(R/R)
>32
(R/R)
128
(R/R)
2
(S/S)
32
(S/R)
256
(R/R)
>256
(R/R)
16
(S/R)
<0.06
(S/S)
<0.06
(S/S)
16
(R/R)
4
(R/R)
dAmpC,
TEM-1 NA
17200/10 M Aspi-rate 66 ICU
>32
(R/R)
>32
(R/R)
<0.12
(S/S)
4
(S/S)
<0.12
(S/S)
<0.12
(S/S)
128
(R/R)
<0.12
(S/S)
0,25
(S/S)
<0.06
(S/S)
<0.12
(S/S)
<0.06
(S/S)
dAmpC,
TEM-1 NA
8549/10 M Resp. 68 Internal 8(S/S)
>32
(R/R)
>256
(R/R)
>256
(R/R)
>256
(R/R)
>256
(R/R)
>128
(R/R)
128
(R/R)
64
(R/R)
0,12
(S/S)
4
(S/S)
8
(R/R)
pdAmpC, 
TEM-1,
CTX-M-1,
OXA-1
S
22040/10 M Umbi-licus <01 Paediatrics
16
(S/S)
>32
(R/R)
>256
(R/R)
>256
(R/R)
>256
(R/R)
>256
(R/R)
>128
(R/R)
64
(R/R)
<0.06
(S/S)
<0.06
(S/S)
>256
(R/R)
256
(R/R)
pdAmpC,
TEM-1,
CTX-M-15,
OXA-1,
SHV-1
NA
30322/10 F Urine 61 Internal 16(S/S)
>32
(R/R)
>256
(R/R)
256
(R/R)
128
(R/R)
256
(R/R)
>128
(R/R)
1
(S/S)
<0.06
(S/S)
<0.06
(S/S)
4
(S/S)
64
(R/R)
dAmpC,
TEM-1,
CMY-2
S
8851/10 F Wound 73 ICU >32
(R/R)
>32
(R/R)
>256
(R/R)
8
(S/S)
32
(S/R)
32
(S/R)
>128
(R/R)
8
(S/S)
<0.06
(S/S)
0,5
(S/S)
>256
(R/R)
2
(S/S)
pdAmpC,
SHV-1 A
34356/10 M Urine <01 Paediatrics 128
(R/R)
>32
(R/R)
>256
(R/R)
256
(R/R)
>256
(R/R)
>256
(R/R)
8
(S/S)
128
(R/R)
<0.06
(S/S)
<0.06
(S/S)
32
(R/R)
32
(R/R)
pdAmpC,
CTX-M-28,
OXA-1
B
13590/10 F Urine 82 Neurology 16(S/S)
>32
(R/R)
>256
(R/R)
256
(R/R)
256
(R/R)
>256
(R/R)
>128
(R/R)
16
(S/R)
<0.06
(S/S)
1
(S/S)
256
(R/R)
128
(R/R)
dAmpC,
TEM-1 B
84874 F Wound 65 Outpatient 16(S/S)
>32
(R/R)
>256
(R/R)
256
(R/R)
128
(R/R)
256
(R/R)
>256
(R/R)
16
(S/R)
<0.06
(S/S)
8
(S/R)
32
(R/R)
16
(R/R)
pdAmpC,
SHV-1 B
13819 F Wound 85 Outpatient >32
(R/R)
>32
(R/R)
32
(R/R)
128
(R/R)
32
(S/R)
4
(S/S)
128
(R/R)
16
(S/R)
<0.06
(S/S)
<0.06
(S/S)
16
(R/R)
1
(S/S) pdAmpC S
10336 M Urine 65 Outpatient >32
(R/R)
>32
(R/R)
>256
(R/R)
64
(R/R)
64
(R/R)
>256
(R/R)
>256
(R/R)
16
(S/R)
0.25
(S/S)
<0.06
(S/S)
>256
(R/R)
4
(R/R)
pdAmpC,
CTX-M-1,
OXA-1
B
18730 M Urine 70 Outpatient >32
(R/R)
>32
(R/R)
>256
(R/R)
128
(R/R)
8
(S/R)
32
(S/R)
>256
(R/R)
<0,12
(S/S)
<0.06
(S/S)
<0.06
(S/S)
16
(R/R)
128
(R/R)
pdAmpC A
30812 F Urine 55 Outpatient >32
(R/R)
>32
(R/R)
>256
(R/R)
64
(R/R)
16
(S/R)
64
(R/R)
>256
(R/R)
0.5
(S/S)
0.12
(S/S)
<0.06
(S/S)
16
(R/R)
2
(S/S) pdAmpC NA
14423 M Wound 60 Outpatient 16(S/S)
>32
(R/R)
>256
(R/R)
16
(S/R)
4
(S/R)
0.25
(S/S)
8
(S/S)
1
(S/S)
0.25
(S/S)
<0.06
(S/S)
128
(R/R)
64
(R/R)
iAmpC,
TEM-1 B
Table 1. Antibiotic susceptibility of 14 AmpC- and/or ESBL-producing Enterobacter cloaceae strains
*AMC, amoxycillin+clavulanic acid; CZ, cefazolin; CXM, cefuroxime; CAZ, ceftazidime;  CTX, cefotaxime; CRO, ceftriaxone; FOX, cefoxitin; 
FEP, cefepime; IMI, imipenem; MEM, meropenem; GM, gentamicin; CIP, ciprofloxacin; F, female, M, male; ICU, Intensive Care Unit; dAmpC, 
derepressed AmpC; pdAmpC, partly derepressed AmpC;  iAmpC, inducible AmpC beta-lactamase; NA, not applicable; S, singleton
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Of 14 ESBL-producing Enterobacter cloacae 
isolates, derepressed, partly derepressed and in-
ducible AmpC β-lactamase was detected in four 
(28.6%), nine (64.3%) and one (7.1%) isolate, 
respectively. Four (out of nine) strains with par-
tly derepressed AmpC beta-lactamase were also 
positive for blaCTX-M gene (two isolates were en-
coding blaCTX-M-1, one isolate blaCTX-M-15 and one 
blaCTX-M-28) and additionally co-produced TEM-
1, SHV-1 or OXA-1. One strain (out of four, 25 
%) with the derepressed AmpC beta-lactamase 
was positive for bla
CMY-2 
and blaTEM-1. Six isolates 
(three dAmpC, two pdAmpC and one iAmpC) 
produced only natural beta-lactamases (four iso-
lates harboured blaTEM-1 and two blaSHV-1). Among 
14 AmpC chromosomally beta-lactamase produ-
cing isolates available for the analysis, four (out 
of 14; 28.6%) isolates did not possess any of na-
tural beta-lactamases (TEM or SHV) (Table 1). 
Antibiotic susceptibility – a comparison of CLSI-
2009 and CLSI-2014 
According to CLSI-2009/CLSI-2014 (14, 15, 
31), a high prevalence of resistance to all cepha-
losporin antibiotics was noticed among 14 AmpC 
and/or ESBL-producing Enterobacter cloacae 
isolates ranging from 71.4-100%/78.6-100%, 
even to cefepime, of 21.4%/57.7%. According 
to both CLSI, gentamicin and ciprofloxacin also 
showed the same low activity, 78.6% and 71.4%, 
respectively. Resistance to imipenem and me-
ropenem was noticed in 7.1%/7.1% and 0/7.1% 
(one isolate for each). 
Multi drug resistance was detected in 78.6% (11 
ou of 14)/92.9% (13 out of 14), according to CLSI-
2009/CLSI-2014, and all MDR isolates were resi-
stant to cephalosporins, cefamicines, amynocligo-
sides, fluoroquinolones and/or carbapenems.
MIC90 for cefepime was 128 µg/mL.
Two (out of four) strains with derepressed AmpC 
beta-lactamase were resistant to cefuroxime, 
ceftazidime, ceftriaxone, cefotaxime, and cipro-
floxacine; one isolate was resistant to cefotaxime, 
but none had an MIC >64 mg/L (Table 1).
All nine strains with partly derepressed AmpC 
beta-lactamase were resistant to cefuroxime and 
gentamicin; all isolates were resistant to cefta-
zidime, the MIC did not exceed 64 mg/L. Six 
(66.7%) isolates were resistant to ciprofloxacin.
One strain with inducible AmpC beta-lactamase 
was susceptible to third and fourth cephalosporin 
generation, but resistant to gentamicin and cipro-
floxacin. 
PFGE typing
Ten isolates were tested for genetic relatedness 
by PFGE typing. Two clones and three singletons 
were identified among E. cloacae (A-B), using a 
similarity threshold of 80%. Clone A consisted 
of one inpatient and one outpatient isolate. Clone 
B comprised two inpatient and three outpatient 
isolates (Figure 1). E. cloacae isolates of clo-
ne A were resistant to cefazolin, cefoxitin, and 
gentamicin, but susceptible to cefotaxime and 
ceftriaxone. In clone B, all isolates were resistant 
to cefotaxime, ceftriaxone, ceftazidime, amino-
glycosides and fluoroquinolones.
DISCUSSION
In this study an occurrence of derepressed, partly 
derepressed and inducible AmpC beta-lactama-
ses was presented as well as characterisation of 
ESBLs in E. cloacae  isolates obtained from in- 
and outpatients, and their antibiotic susceptibility 
according to the breakpoint changes in  CLSI-
2009/CLSI-2014 documents.
The partly derepressed AmpC β-lactamases were 
the most prevalent type in AmpC carrying E. 
cloacae isolates  in this study which is in the con-
trast to the report from Vienna (Austria) with a 
high prevalence of inducible AmpC β-lactamases 
in E. cloacae (44%) (10), but it is similar to re-
ports from France, Greece, Italy, Latvia, Luxem-
bourg, Slovenia, Israel and Spain (25). Partly 
derepressed AmpC β-lactamase producing isola-
tes in this study co-harboured CTX-M-1, CTX-
M-15 and CTX-M-28. 
In bacterial genera, such as Enterobacter spp., 
with the presence of inducible AmpC chromoso-
mal enzymes, a detection of ESBLs is difficult 
(26). AmpC beta-lactamases in E. cloacae are 
mostly produced in the presence of clavulanate 
resulting in difficulties to detect ESBLs, because 
they mask a synergy between amoxicillin-clavu-
lanate and cephalosporin disks (27). 
Isolates co-producing both ESBL and AmpC 
β-lactamases have become more frequent 
worldwide (28). Prevalence of isolates co-pro-
ducing both beta-lactamases in this study is low 
7(five, out of 14, 36%) and it is similar to a report 
from Asian-Pacific region (23%) (28). According 
to Jeong et al. if ESBL double disc synergy test is 
negative or inconclusive, and expanded-spectrum 
cephalosporins or aztreonam susceptibility is redu-
ced (MIC ≥4 µg/ml), the isolate should be retested 
by a method that is unaffected by AmpC beta-lacta-
mases, e. g. with addition of cloxacilin in the cultu-
re medium or AmpC inhibitor (boronic acid) (29). 
In this study there were no ambiguous results. 
Strains with AmpC genes are often resistant to 
multiple agents making therapeutic selection of 
effective antibiotic difficult (30). Most cephalos-
porins and penicillins should be avoided because 
of development of resistance during the therapy 
due to the potential for AmpC induction or se-
lection of mutants (30). Unsatisfactory clinical 
outcome, with ceftazidime, cefotaxime and other 
cephalosporins is well documented (30).
Available inpatients data from this study showed 
that cefazolin was mostly used drug in the tre-
atment of infections caused by E. cloacae iso-
lates carrying AmpC β-lactamases, but no data 
available for clinical outcome of the infections. 
Clinical failure even in cefotaxime treatment of 
E. cloacae infections was reported by Crowey et 
al. showing that although cefotaxime had good in 
vitro susceptibility (MIC 2 mg/L) on MIC testing 
at the standard inoculum of 105 cfu/mL, the MIC 
rose dramatically when the inoculum was increa-
sed to 107 cfu/mL (64 mg/L) (26). Resistance rate 
for cefotaxime in the present study was double 
rose applying CLSI-2014 guideline (31) compa-
ring to CLSI-2009 guideline (50%/93%) leading 
in therapeutic failure. 
Cefepime is a poor inducer of AmpC beta-
lactamase and it is stable to hydrolysis by these 
β-lactamases, thus the majority of  AmpC-produ-
cing isolates are cefepime susceptible (30).
In this study, 21.4% (three isolates, all ESBL 
producers) were resistant to cefepime using MIC 
≥32 mg/L breakpoint, and it is in accordance with 
reports from Austria (13 %) (10) and the Nether-
lands (14 %) (32), but in the report from China 
100% resistance to cefepime is noticed (33). It is 
very worrying, because in this study additional 
five isolates (out of 14) have shown intermediate 
susceptibility to cefepime with the MIC of 16 µg/
mL, which is even higher than from Pittsburgh 
report (three out of 15, MIC of 16 mg/L) (13). 
MIC90 of 128 µg/mL for cefepime in the pre-
sent study was higher than in the report from 
Pittsburgh where the MIC90 of 64µg/mL was no-
ticed (13) suggesting cefepime could not be used 
in the first line therapy. 
According to CLSI 2014 and EUCAST 2014 gu-
idelines (31, 34), prevalence of resistance to cefe-
pime in the present study was 57% (MIC ≥16) and 
64% (MIC ≥4), respectively, which is more than 
double comparing to CLSI 2009 (21%; MIC ≥32). 
Almost all isolates in this study were suscepti-
ble to meropenem and imipenem, similarly to 
the report from the Netherlands (32). Resistance 
rates for aminoglycosides and fluoroquinolones 
of 79% and 71%, respectively, are similar to the 
report from China (33) and Spain (35). Usually, 
carbapenem and cefepime therapy has been 
successful (33).
The definition of MDR (acquired non-suscepti-
bility to at least one agent in three or more an-
timicrobial categories) is most frequently used 
for Gram-negative bacteria (36). In the case of 
Enterobacter spp. which has intrinsic resistance 
to the first and second cefalosporin generation, 
cefamycine, and penicillin+beta-lactam inhibi-
tors, these agents/category should not be consi-
dered for detection of MDR (36). In this study, 
according to CLSI-2009/2014 guidelines (15, 31, 
36) and EUCAST-2014 (34), 79%, 93% and 86% 
were detected as MDR isolates. Having in mind 
that Enterobacter spp. are either very resistant to 
many agents or could develop resistance during 
the course of antimicrobial therapy, the choice of 
appropriate antimicrobial agents is complicated 
(37). Colistin, polymyxin B or tigecycline are be-
ing used more frequently to treat serious infecti-
ons caused by MDR E. cloacae, as monotherapy 
or in combination with other antibiotics (37).
Two PFGE clones were detected among both in-
patient and outpatient AmpC carrying beta-lacta-
mase producing E. cloacae isolates, indicating 
that beta-lactamase production was not due to the 
spreading of a single clone, but rather due to the 
horizontal transfer of plasmids containing diffe-
rent genes between different species (21). Diffe-
rent antibiotic resistance phenotypes of E. cloa-
cae isolates in two clusters, as well as in isolates 
in the same cluster containing different genes 
(blaTEM, blaSHV, blaCTX-M) has been found in this 
study. It is similar to the report from Spain (35).
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Investigation of risk factors and identification of 
infections caused by E. cloacae with the chromo-
somal AmpC beta-lactamases are important for 
the management and control of health care asso-
ciated infections (38-40).
The main limitation of this study is a small 
number of AmpC- and/or ESBL-producing En-
terobacter  spp. isolates collected/available for 
the analysis because of the short time span (six 
months) and their low prevalence in infections.
In conclusion, the prevalence of ESBLs in E. 
cloacae isolates causing infections in this stu-
dy is low. Partly derepressed mutants are most 
frequent ones. Reduced susceptibility among 
E. cloacae isolates is a matter of an increasing 
concern worldwide. Molecular characterization 
of these strains is important for the detection of 
the sources of infections and mode of their spre-
ading, which is the main step in order to design 
targeted infection control strategies. It is impor-
tant to include phenotypic detection of AmpC 
beta-lactamases in routine laboratory practice. 
Further clinical studies are needed to evaluate 
large numbers of patients treated with cefepime 
or carbapenems to assess the efficacy of these 
drugs in the treatment of AmpC beta-lactamase 
producing E. cloacae infections.
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